SEATTLE, Dec. 22 /PRNewswire-FirstCall/ -- Pacific Biometrics, Inc. , today announced that Dr. Michael Murphy has been appointed to the position of Chief Operating Officer.
Dr. Murphy was previously Technical Director at Laboratory Corporation of America (LabCorp(R)), where he was responsible for three of its West Division laboratories (Northwest, Reno, and Salt Lake regions). In this role, he provided technical leadership for all aspects of operations, including the operational re-design of the labs for cost reductions and new technology introduction. Dr. Murphy has also served in leadership positions at a number of healthcare and research centers, including Eastern Maine Medical Center (Laboratory Director) and CompuLab Corporation (Director of Professional Services).
“As a key member of the PBI senior management team, Dr. Murphy has played a critical role in growing and nurturing our dynamic service business model,” commented Ron Helm, Chairman and Chief Executive Officer of Pacific Biometrics, Inc. “He has proven to be an outstanding member of our executive team, has played a critical role in shaping the Company’s business strategy, and has made numerous material contributions to the execution of our operating plans. It is a great pleasure to announce his appointment as Chief Operating Officer, thereby further solidifying the Company’s senior management team. We look forward to Michael’s leadership as PBI continues expands into new areas - most notably clinical biomarker services - and seeks to enhance shareholder value by building upon the record earnings we reported in Fiscal 2009.”
Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI’s clients include many of the world’s largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing ligand-binding assays for novel clinical biomarkers, immunogenicity testing, cell based assay testing and multiplex testing.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Pacific Biometrics, Inc.
